Citation only
via OpenAlex
Short-term rapamycin treatment of an older human cohort alters immune and inflammatory markers but fails to re-set the epigenetic biological clock 2259884
Ellen Kraig, Leslie A. Linehan, Xiang Gao, Adriana Benavides, Joshua Zhang, Brett C. Ginsburg, Wouter Koek, Qunfeng Dong, Steve Horvath, Dean L. Kellogg
The Journal of Immunology · 2026
Epigenetic alterations
Dysbiosis
Deregulated nutrient-sensing
Chronic inflammation
Rapamycin / mTOR inhibition
Human
Mouse
Abstract
Abstract Introduction Pharmacological inhibition of the mTOR(definition) pathway with rapamycin(definition) (RAPA) extends lifespan and improves aspects of healthspan(definition) in mice. Enhanced longevity was achieved even when treatment was initiated later in life, suggesting that RAPA could be used to slow progression of age-associated pathologies in older humans. Moreover, in some animal models, intermittent treatment with mTOR inhibitors elicited long-term beneficial outcomes while obviating adverse effects. Methods To determine whether short-term RAPA treatment was able to reverse age-associated deficits in humans, we undertook a placebo-controlled study of 1mg/d RAPA in older human subjects (PMID: 29408453). Using specimens available from this pilot trial, we have now characterized potential changes in immune, epigenetic, and microbiome parameters known to be negatively impacted by aging. Results RAPA effects on immune cells were observed, including increases in a unique CD11b+ myeloid subset which shares some features with MDSCs and in foxp3+ TREGS. An increase in suppressive cell subsets may be beneficial in preventing autoimmunity. Indeed, the 8-week RAPA treatment slightly decreased autoantibody levels in subjects with detectable titers. Treatment was also associated with concomitant decreases in sICAM-I and increases in sRAGE. Given the interplay between the microbiome, inflammation, and aging, it was of interest that the gut microbiota became more diverse within the first 6 weeks of RAPA treatment. On the other hand, short-term RAPA treatment did not alter the “epigenetic age” in PBMCs. Conclusion Although many RAPA effects could be elicited by short-term inhibition of mTOR, other parameters will likely require a longer treatment. To explore this possibility, we were recently funded for a PK/PD analysis of mTOR inhibition in older humans. The goal is to identify the optimal drug (RAPA vs. Everolimus), dose, and dosing frequency (daily vs. intermittent) that can be administered safely, tolerably, and long-term in humans (ages 65-90 yrs). Funding Source NIA [Pepper Center pilot grants; NIA/NIH R21; and NIA/NIH U01] Topic Categories Immune Mechanisms of Human Disease (HUM)
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/jimmun/vkag141.802
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Kraig, E., Linehan, L.A., Gao, X., Benavides, A., Zhang, J., Ginsburg, B.C., Koek, W., Dong, Q., Horvath, S., & Kellogg, D.L. (2026). Short-term rapamycin treatment of an older human cohort alters immune and inflammatory markers but fails to re-set the epigenetic biological clock 2259884. <em>The Journal of Immunology</em>. https://doi.org/10.1093/jimmun/vkag141.802
Vancouver
Kraig E, Linehan LA, Gao X, Benavides A, Zhang J, Ginsburg BC, et al. Short-term rapamycin treatment of an older human cohort alters immune and inflammatory markers but fails to re-set the epigenetic biological clock 2259884. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag141.802.
BibTeX
@article{ellen2026Shortt,
title = {Short-term rapamycin treatment of an older human cohort alters immune and inflammatory markers but fails to re-set the epigenetic biological clock 2259884},
author = {Ellen Kraig and Leslie A. Linehan and Xiang Gao and Adriana Benavides and Joshua Zhang and Brett C. Ginsburg and Wouter Koek and Qunfeng Dong and Steve Horvath and Dean L. Kellogg},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag141.802},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2017
Open access · CC-BY
Short‐term rapamycin treatment increases ovarian lifespan in young and middle‐aged female mice
European Journal of Heart Failure 2018
Open access · OA
Frailty in TOPCAT: A Deep Dive into the Deficit Index Approach for Defining Frailty
Universitas Indonesia 2015
Open access · US-GOV
Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly
Antioxidants 2026
Open access · CC-BY
Fisetin Attenuates D-Gal-Induced Ovarian Aging by Modulating Mitophagy via the AMPK/mTOR Pathway
PLoS ONE 2012
Open access · CC-BY
Long-Term Bezafibrate Treatment Improves Skin and Spleen Phenotypes of the mtDNA Mutator Mouse
Frontiers in Endocrinology 2021
Open access · CC-BY